Skip to main content

Table 1 Demographic, clinical, and pathological characteristics of patients

From: UDP-glucuronosyltransferases and biochemical recurrence in prostate cancer progression

  All patients
(N = 190)
Age, M (Q1-Q3) 63 (58-67)
Race, n(%)
 Non-black 99 (52)
 Black 91 (48)
Year of Surgery, M (Q1-Q3) 2001 (1997-2002)
PSA (ng/mL), M (Q1-Q3) 7.4 (5.1-11.1)
Pathological Gleason, n(%):
 2 – 6 39 (20)
 (3 + 4) 100 (53)
 (4 + 3) – 10 51 (27)
Positive Margins, n(%) 115 (61)
Seminal Vesicle Invasion, n(%) 28 (15)
Extracapsular Extension, n(%) 51 (27)
Positive Lymph Nodes, n(%) 1 (<1)
Average % Cells Positive for UGT2B15, M(Q1-Q3) 39 (24-61)
Average % Cells Positive for UGT2B17, M(Q1-Q3) 74 (59-86)
Average % Cells Positive for UGT2B28, M(Q1-Q3) 77 (60-91)
UGT2B15 H-score, M(Q1-Q3) 40 (24-63)
UGT2B17 H-score, M(Q1-Q3) 76 (59-92)
UGT2B28 H-score, M(Q1-Q3) 86 (64-107)
PSA Follow-up (months), M(Q1-Q3) 118 (85-144)
  1. SD standard deviation, M median; Q1 25th percentile; Q3 75th percentile; BMI body mass index, PSA prostate specific antigen